Kymera Therapeutics, Inc. (KYMR)
KYMR Stock Price Chart
Explore Kymera Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze KYMR price movements and trends.
KYMR Company Profile
Discover essential business fundamentals and corporate details for Kymera Therapeutics, Inc. (KYMR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Aug 2020
Employees
208.00
Website
https://www.kymeratx.comCEO
Nello Mainolfi
Description
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
KYMR Financial Timeline
Browse a chronological timeline of Kymera Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.73, while revenue estimate is $31.17m.
Earnings released on 30 Apr 2026
EPS came in at -$0.71 surpassing the estimated -$0.89 by +20.22%, while revenue for the quarter reached $34.37m , beating expectations by +315.71%.
Earnings released on 26 Feb 2026
EPS came in at -$0.97 falling short of the estimated -$0.78 by -23.78%, while revenue for the quarter reached $2.87m , missing expectations by -80.92%.
Earnings released on 4 Nov 2025
EPS came in at -$0.90 falling short of the estimated -$0.71 by -26.76%, while revenue for the quarter reached $2.76m , missing expectations by -80.87%.
Earnings released on 11 Aug 2025
EPS came in at -$0.95 falling short of the estimated -$0.83 by -14.46%, while revenue for the quarter reached $11.48m , missing expectations by -33.01%.
Earnings released on 9 May 2025
EPS came in at -$0.82 surpassing the estimated -$0.92 by +10.87%, while revenue for the quarter reached $22.10m , beating expectations by +78.49%.
Earnings released on 27 Feb 2025
EPS came in at -$0.88 falling short of the estimated -$0.76 by -15.79%, while revenue for the quarter reached $7.39m , missing expectations by -55.67%.
Earnings released on 31 Oct 2024
EPS came in at -$0.82 surpassing the estimated -$0.83 by +1.20%, while revenue for the quarter reached $3.74m , missing expectations by -75.41%.
Earnings released on 7 Aug 2024
EPS came in at -$0.58 surpassing the estimated -$0.69 by +15.94%, while revenue for the quarter reached $25.65m , beating expectations by +104.38%.
Earnings released on 2 May 2024
EPS came in at -$0.69 surpassing the estimated -$0.73 by +5.48%, while revenue for the quarter reached $10.29m , missing expectations by -24.86%.
Earnings released on 22 Feb 2024
EPS came in at -$0.25 surpassing the estimated -$0.44 by +43.18%, while revenue for the quarter reached $47.89m , beating expectations by +14.12%.
Earnings released on 2 Nov 2023
EPS came in at -$0.90 falling short of the estimated -$0.73 by -23.29%, while revenue for the quarter reached $4.73m , missing expectations by -70.39%.
Earnings released on 3 Aug 2023
EPS came in at -$0.67 surpassing the estimated -$0.70 by +4.29%, while revenue for the quarter reached $16.51m , beating expectations by +17.45%.
Earnings released on 4 May 2023
EPS came in at -$0.70 falling short of the estimated -$0.69 by -1.45%, while revenue for the quarter reached $9.47m , missing expectations by -33.10%.
Earnings released on 23 Feb 2023
EPS came in at -$0.60 falling short of the estimated -$0.57 by -5.26%, while revenue for the quarter reached $16.14m , missing expectations by -26.82%.
Earnings released on 3 Nov 2022
EPS came in at -$0.79 falling short of the estimated -$0.70 by -12.86%, while revenue for the quarter reached $9.55m , missing expectations by -38.43%.
Earnings released on 9 Aug 2022
EPS came in at -$0.78 falling short of the estimated -$0.68 by -14.71%, while revenue for the quarter reached $11.51m , missing expectations by -19.13%.
Earnings released on 3 May 2022
EPS came in at -$0.71 falling short of the estimated -$0.67 by -5.97%, while revenue for the quarter reached $9.62m , missing expectations by -48.67%.
Earnings released on 24 Feb 2022
EPS came in at -$0.66 falling short of the estimated -$0.36 by -83.33%, while revenue for the quarter reached $15.28m , missing expectations by -28.33%.
Earnings released on 10 Nov 2021
EPS came in at -$0.56 falling short of the estimated -$0.34 by -64.71%, while revenue for the quarter reached $20.34m , beating expectations by +14.48%.
Earnings released on 6 Aug 2021
EPS came in at -$0.55 falling short of the estimated -$0.21 by -161.90%, while revenue for the quarter reached $18.52m , meeting expectations.
KYMR Stock Performance
Access detailed KYMR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
